Bioactive nanotherapeutic trends to combat triple negative breast cancer.
Biomimetic nanoparticles
Breast cancer treatment
Chemotherapy
Membrane cloaked nanoparticles
Nanomedicine
Nanoparticles
Triple negative breast cancer
Journal
Bioactive materials
ISSN: 2452-199X
Titre abrégé: Bioact Mater
Pays: China
ID NLM: 101685294
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
10
2020
revised:
27
02
2021
accepted:
28
02
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability, targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen. This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked (biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting nanomedicine for effective management of breast cancer, especially TNBC.
Identifiants
pubmed: 33778204
doi: 10.1016/j.bioactmat.2021.02.037
pii: S2452-199X(21)00099-2
pmc: PMC7970221
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3269-3287Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
Authors declare no potential conflict of interests.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Methods Mol Biol. 2010;624:25-37
pubmed: 20217587
PLoS One. 2012;7(2):e31070
pubmed: 22355336
Cancer Discov. 2019 Feb;9(2):176-198
pubmed: 30679171
Sci Transl Med. 2014 Jan 1;6(217):217ra3
pubmed: 24382895
Molecules. 2020 Feb 26;25(5):
pubmed: 32110917
Ann Oncol. 2008 May;19(5):861-70
pubmed: 18174609
Anticancer Drugs. 2001 Apr;12(4):315-23
pubmed: 11335787
Onco Targets Ther. 2017 Sep 20;10:4675-4685
pubmed: 29033586
J Control Release. 2007 Apr 2;118(2):145-60
pubmed: 17270305
Adv Mater. 2018 May;30(22):e1706245
pubmed: 29577477
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
PLoS One. 2013 Nov 13;8(11):e80780
pubmed: 24236201
Clin Cancer Res. 2004 Jun 1;10(11):3708-16
pubmed: 15173077
Cancer Chemother Pharmacol. 2000;46(5):416-22
pubmed: 11127947
Trends Mol Med. 2002 Dec;8(12):571-6
pubmed: 12470990
Cancer Chemother Pharmacol. 2008 Sep;62(4):667-72
pubmed: 18064460
Thromb Haemost. 1995 Jul;74(1):282-90
pubmed: 8578473
Biomaterials. 2014 Jul;35(20):5347-5358
pubmed: 24726747
Biomed Res Int. 2015;2015:382745
pubmed: 25759817
Mol Pharm. 2018 May 7;15(5):1755-1765
pubmed: 29528655
Biomed Res Int. 2013;2013:960821
pubmed: 23865076
Nanoscale. 2016 Apr 7;8(13):6981-5
pubmed: 26975904
J Pharm Sci. 2003 Jul;92(7):1343-55
pubmed: 12820139
Nat Rev Cancer. 2002 Oct;2(10):750-63
pubmed: 12360278
PLoS One. 2012;7(7):e41171
pubmed: 22911754
Nanomedicine (Lond). 2017 Aug;12(16):2007-2019
pubmed: 28745122
Theranostics. 2015 Apr 27;5(8):863-81
pubmed: 26000058
Nanomedicine (Lond). 2014 Apr;9(5):561-4
pubmed: 24827837
J Control Release. 2016 Oct 28;240:527-540
pubmed: 27422609
Pharmacol Ther. 2021 Jul;223:107800
pubmed: 33421449
Nanomedicine. 2008 Dec;4(4):273-82
pubmed: 18640076
Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-69-S17-71
pubmed: 9374098
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Cell Mol Life Sci. 2017 Oct;74(19):3491-3507
pubmed: 28488110
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
pubmed: 16606824
Cancer Res Treat. 2017 Jul;49(3):569-577
pubmed: 27618821
J Clin Oncol. 2005 Aug 20;23(24):5542-51
pubmed: 16110015
Eur J Cancer. 2008 Dec;44(18):2799-805
pubmed: 19008097
J Clin Oncol. 2002 Mar 15;20(6):1456-66
pubmed: 11896092
Neuro Oncol. 2017 Oct 19;19(11):1481-1493
pubmed: 28486691
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
J Clin Oncol. 2009 Mar 10;27(8):1168-76
pubmed: 19204205
Cancers (Basel). 2011 Jul 15;3(3):2888-903
pubmed: 24212938
Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9
pubmed: 25417902
Biomaterials. 2016 Jan;76:52-65
pubmed: 26519648
Crit Rev Ther Drug Carrier Syst. 2003;20(5):357-403
pubmed: 14959789
ACS Nano. 2010 Sep 28;4(9):4971-8
pubmed: 20738118
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Breast Cancer Res Treat. 2016 Feb;156(1):125-34
pubmed: 26941199
N Engl J Med. 2014 Jan 30;370(5):479-80
pubmed: 24476438
Int J Cancer. 2009 Aug 15;125(4):887-93
pubmed: 19431148
Drug Deliv. 2003 Jan-Mar;10(1):9-20
pubmed: 12554359
Nat Biotechnol. 2011 Apr;29(4):341-5
pubmed: 21423189
Mol Cancer Ther. 2013 Nov;12(11):2389-99
pubmed: 24002934
Med Oncol. 2012 Jun;29(2):526-33
pubmed: 21519872
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
J Surg Res. 2014 Mar;187(1):19-23
pubmed: 24360118
Nat Med. 2010 Feb;16(2):219-23
pubmed: 20081861
Theranostics. 2017 Jan 25;7(3):751-763
pubmed: 28255364
Lancet Oncol. 2016 Mar;17(3):345-356
pubmed: 26869049
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
J Control Release. 2013 Nov 10;171(3):330-8
pubmed: 23714121
Drug Resist Updat. 2010 Aug-Oct;13(4-5):109-18
pubmed: 20692200
J Exp Clin Cancer Res. 2019 Oct 28;38(1):430
pubmed: 31661003
J Interferon Cytokine Res. 2011 Jul;31(7):545-52
pubmed: 21323567
J Clin Oncol. 2005 Nov 1;23(31):7785-93
pubmed: 16258082
Am J Surg. 2017 Nov;214(5):938-944
pubmed: 28830617
Nat Nanotechnol. 2017 Jul;12(7):692-700
pubmed: 28650441
Eur J Cancer. 2009 Sep;45 Suppl 1:27-40
pubmed: 19775602
Nanomaterials (Basel). 2018 Nov 08;8(11):
pubmed: 30412991
J Thorac Oncol. 2008 Jun;3(6):623-30
pubmed: 18520802
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Biomaterials. 2013 Dec;34(38):10160-71
pubmed: 24090836
Hum Pathol. 2012 Oct;43(10):1638-44
pubmed: 22436627
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):73-87
pubmed: 27189231
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):118-27
pubmed: 24118902
Adv Mater. 2017 Apr;29(13):
pubmed: 28160337
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Clin Ther. 2013 Dec;35(12):1946-54
pubmed: 24290734
Nano Lett. 2007 Dec;7(12):3759-65
pubmed: 17979310
Protein Pept Lett. 2013 Apr;20(4):392-402
pubmed: 23016580
ACS Nano. 2015 Jul 28;9(7):6918-33
pubmed: 26153897
Cancer Biol Ther. 2012 May;13(7):472-6
pubmed: 22526226
Cancer Res. 2010 Jun 1;70(11):4550-9
pubmed: 20484031
Nanotechnology. 2009 Oct 28;20(43):434001
pubmed: 19801758
Clin Cancer Res. 2003 Jun;9(6):2335-41
pubmed: 12796403
Acta Pharm Sin B. 2019 Jul;9(4):675-689
pubmed: 31384529
Annu Rev Pathol. 2011;6:19-48
pubmed: 20887193
Br J Haematol. 2011 Apr;153(1):58-65
pubmed: 21332712
Mol Pharm. 2019 Aug 5;16(8):3414-3429
pubmed: 31194563
Front Chem. 2014 Nov 26;2:105
pubmed: 25505783
Ann Intern Med. 1999 Feb 16;130(4 Pt 1):270-7
pubmed: 10068384
Int J Nanomedicine. 2018 Sep 11;13:5347-5359
pubmed: 30254439
Eur J Cancer. 2013 Jun;49(9):2077-85
pubmed: 23583440
Am J Hematol. 2015 Sep;90(9):811-8
pubmed: 26094614
Adv Mater. 2017 Apr;29(16):
pubmed: 28199033
ACS Nano. 2013 Sep 24;7(9):7698-710
pubmed: 24004438
Nature. 2015 Oct 1;526(7571):118-21
pubmed: 26374997
Biomaterials. 2012 Apr;33(10):2961-70
pubmed: 22245557
Cancer Biol Ther. 2010 Nov 15;10(10):955-60
pubmed: 21057215
Chem Biol Interact. 2008 Jan 30;171(2):195-203
pubmed: 17376417
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Biomaterials. 2014 Mar;35(9):3044-51
pubmed: 24439415
Sci Rep. 2015 Oct 26;5:15636
pubmed: 26497063
J Thorac Dis. 2015 Jul;7(7):1111-2
pubmed: 26380724
Asia Pac J Clin Oncol. 2013 Jun;9(2):176-81
pubmed: 23176568
Biomaterials. 2016 Sep;102:231-8
pubmed: 27344366
Adv Healthc Mater. 2016 May;5(9):1088-93
pubmed: 26989887
J Surg Oncol. 2011 Mar 15;103(4):317-25
pubmed: 21337565
Nat Nanotechnol. 2013 Jan;8(1):61-8
pubmed: 23241654
Carcinogenesis. 2012 May;33(5):949-55
pubmed: 22425643
J Clin Oncol. 2015 Jul 20;33(21):2361-9
pubmed: 26056183
Br J Cancer. 1999 Feb;79(5-6):991-5
pubmed: 10070902
Ann Oncol. 2014 Apr;25(4):824-831
pubmed: 24667715
Nat Nanotechnol. 2013 Dec;8(12):933-8
pubmed: 24292514
Blood Rev. 2014 Jul;28(4):155-66
pubmed: 24826991
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
pubmed: 16115903
Head Neck. 2014 Jul;36(7):976-84
pubmed: 23733258
Breast Cancer Res Treat. 2009 May;115(2):359-63
pubmed: 18649131
Breast Cancer Res Treat. 2008 Mar;108(2):241-50
pubmed: 17476588
Breast Cancer Res. 2013;15(4):207
pubmed: 23905544
N Engl J Med. 2015 May 14;372(20):1882-5
pubmed: 25902384
Blood. 2001 Jan 15;97(2):339-45
pubmed: 11154206
Pharm Res. 2009 May;26(5):1025-58
pubmed: 19107579
ACS Nano. 2017 Feb 28;11(2):1397-1411
pubmed: 28075552
J Clin Oncol. 1998 Oct;16(10):3439-60
pubmed: 9779724
Biochem Biophys Res Commun. 2017 Jun 24;488(2):322-328
pubmed: 28495530
Biomaterials. 2013 Sep;34(28):6949-56
pubmed: 23777919
J Control Release. 2016 Feb 28;224:208-216
pubmed: 26778696
Blood. 2013 Jul 11;122(2):253-61
pubmed: 23652806
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):10980-5
pubmed: 21690347
Drug Deliv. 2020 Dec;27(1):1-14
pubmed: 31818156
J Clin Oncol. 2010 Mar 1;28(7):1145-53
pubmed: 20100965
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Sep;9(5):
pubmed: 28116852
J Control Release. 2014 Sep 28;190:465-76
pubmed: 24993430
Ann Oncol. 2008 Jul;19(7):1261-1265
pubmed: 18325917
Nanoscale. 2015 Mar 7;7(9):4020-30
pubmed: 25653083
Oncotarget. 2015 May 30;6(15):12890-908
pubmed: 25973541
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Trends Mol Med. 2014 Jul;20(7):385-93
pubmed: 24703619
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
Chem Commun (Camb). 2011 May 14;47(18):5235-7
pubmed: 21451845
J Control Release. 2015 Apr 28;204:11-9
pubmed: 25646783
Iran J Cancer Prev. 2016 Apr 24;9(2):e3966
pubmed: 27482328
Clin Cancer Res. 2011 Apr 1;17(7):1867-74
pubmed: 21325075
Mol Cancer. 2010 Sep 21;9:253
pubmed: 20858281
J Clin Invest. 2005 Dec;115(12):3348-54
pubmed: 16322779
J Clin Oncol. 1998 Oct;16(10):3353-61
pubmed: 9779712
Ann Oncol. 2015 Jan;26(1):58-64
pubmed: 25344362
Am J Transl Res. 2012;4(4):376-89
pubmed: 23145206
Clin Breast Cancer. 2006 Aug;7(3):270-7
pubmed: 16942645
Small. 2019 Feb;15(5):e1804191
pubmed: 30549431
Front Immunol. 2014 Oct 07;5:489
pubmed: 25339957
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):88-103
pubmed: 26941164
Oncotarget. 2016 May 31;7(22):32462-77
pubmed: 27074574
Biochim Biophys Acta. 2016 Mar;1863(3):392-400
pubmed: 26193075
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
N Engl J Med. 2007 Oct 11;357(15):1496-506
pubmed: 17928597
Cancer. 2007 Jan 1;109(1):25-32
pubmed: 17146782
J Clin Oncol. 2014 Nov 10;32(32):3619-25
pubmed: 25267761
Theranostics. 2014 Jul 13;4(9):931-44
pubmed: 25057317
Palliat Support Care. 2015 Dec;13(6):1771-80
pubmed: 25728373
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
Br J Cancer. 2005 Apr 11;92(7):1240-6
pubmed: 15785749
Theranostics. 2017 Feb 26;7(5):1062-1071
pubmed: 28435448
Indian Dermatol Online J. 2013 Oct;4(4):267-72
pubmed: 24350003
Am J Cardiol. 2015 Dec 1;116(11):1752-5
pubmed: 26433273
Biotechnol Bioeng. 2014 Sep;111(9):1699-716
pubmed: 24916780
Clin Cancer Res. 2005 Nov 1;11(21):7834-40
pubmed: 16278406
J Clin Oncol. 2009 Oct 1;27(28):4693-700
pubmed: 19720916
Annu Rev Immunol. 2009;27:669-92
pubmed: 19132917
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390
Adv Mater. 2015 Nov 25;27(44):7043-50
pubmed: 26416431
Cancer Lett. 2010 Dec 1;298(1):34-49
pubmed: 20594639
Nat Rev Drug Discov. 2015 Apr;14(4):239-47
pubmed: 25598505
Mol Med Rep. 2013 Mar;7(3):947-52
pubmed: 23291923
Nano Lett. 2017 Sep 13;17(9):5546-5554
pubmed: 28758755
Int J Nanomedicine. 2009;4:99-105
pubmed: 19516888
Transfus Med Rev. 2006 Jan;20(1):1-26
pubmed: 16373184
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 May-Jun;3(3):269-81
pubmed: 21046660
Eur J Pharm Sci. 2017 Jan 1;96:115-128
pubmed: 27496050
Acta Pharm Sin B. 2018 Jan;8(1):14-22
pubmed: 29872619
Ann Oncol. 2010 Feb;21(2):382-388
pubmed: 19633055
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1108-12
pubmed: 15894660
ACS Nano. 2013 Jul 23;7(7):5675-83
pubmed: 23697579
Annu Rev Pathol. 2014;9:181-218
pubmed: 24050624
Polymers (Basel). 2018 Sep 03;10(9):
pubmed: 30960908
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Clin Cancer Res. 2019 Apr 1;25(7):2072-2079
pubmed: 30635336
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
J Drug Target. 2013 Dec;21(10):956-967
pubmed: 24032759
Lancet Oncol. 2017 Oct;18(10):1360-1372
pubmed: 28800861
Clin Cancer Res. 2008 Sep 15;14(18):5856-63
pubmed: 18794097
Blood. 2015 Jul 30;126(5):582-8
pubmed: 26109205
Cancer Res. 2008 Aug 15;68(16):6652-60
pubmed: 18701489